Kentucky Pilot Program to Reimburse Medicare Patients for Hemp Products

New initiative aims to improve access to hemp-derived CBD and other products for qualifying Medicare beneficiaries.

Apr. 8, 2026 at 9:50pm

Got story updates? Submit your updates here. ›

An extreme close-up X-ray photograph revealing the delicate, glowing internal structures of a hemp plant leaf against a dark background, conceptually illustrating the medical potential of hemp-derived products.A new Kentucky pilot program aims to make hemp-derived CBD products more accessible to Medicare patients, but the industry faces looming federal regulations that could restrict availability.Louisville Today

A new pilot program in Kentucky will allow Medicare patients to be reimbursed up to $500 per year for the purchase of hemp-derived products such as CBD oil. The program comes at a critical time for the industry, which faces a federal deadline that could ban most current hemp products on the market.

Why it matters

This pilot program represents a significant step forward for the hemp industry, which has faced regulatory uncertainty and limited access for consumers, especially older adults on Medicare. If successful, the program could unlock a massive new market and spur further research and development of hemp-based therapeutics.

The details

The Centers for Medicare and Medicaid Services announced the new pilot program, which will make hemp-derived CBD products available to Medicare beneficiaries through participating accountable care organizations. Qualifying patients could be reimbursed up to $500 per year for products like CBD oil. This comes after President Trump signed an executive order in December 2025 to loosen restrictions on marijuana and improve access to hemp. However, the industry faces a looming federal deadline that could ban most hemp products currently on the shelves due to a new cap on THC content.

  • The new pilot program in Kentucky starts this month (April 2026).
  • In December 2025, President Trump signed an executive order to loosen restrictions on marijuana and improve access to hemp.
  • In November 2025, Congress enacted a cap of 0.4 milligrams of THC per container, effectively banning most hemp products, set to take effect later in 2026.

The players

Cornbread Hemp

A Louisville-based company that is the largest USDA-certified organic producer of full-spectrum CBD products.

Jim Higdon

Co-founder of Cornbread Hemp, who says the pilot program represents a "giant step forward" for the hemp industry.

Centers for Medicare and Medicaid Services

The federal agency that announced the new pilot program to reimburse Medicare patients for hemp-derived products.

President Donald Trump

Signed an executive order in December 2025 to loosen restrictions on marijuana and improve access to hemp.

U.S. Congress

Enacted a cap of 0.4 milligrams of THC per container in November 2025, effectively banning most hemp products.

Got photos? Submit your photos here. ›

What they’re saying

“We're the largest USDA-certified organic producer of full-spectrum CBD products.”

— Jim Higdon, Co-founder, Cornbread Hemp

“So $500 per Medicare beneficiary times the number of Americans on Medicare equals something like $32 billion in potential annual revenue from this program. So it is a giant step forward for the industry as soon as we figure out problems on Capitol Hill.”

— Jim Higdon, Co-founder, Cornbread Hemp

“It's essentially a vote of confidence in our industry that our industry will figure this out with stakeholders on Capitol Hill in Washington, and we'll be able to keep these products legal in a responsible way after that deadline.”

— Jim Higdon, Co-founder, Cornbread Hemp

What’s next

Industry stakeholders are working with lawmakers in Washington to address the federal cap on THC content that could ban most hemp products later this year, before the new Medicare reimbursement program takes effect.

The takeaway

This pilot program represents a significant breakthrough for the hemp industry, unlocking a massive new market of Medicare patients and signaling growing acceptance of hemp-derived products. However, the industry still faces regulatory hurdles that must be resolved to ensure the long-term viability of this emerging market.